Guangzhou Wondfo Biotech Co.Ltd(300482) (SZ Guangzhou Wondfo Biotech Co.Ltd(300482) , closing price: 59.76 yuan) announced on March 13 that recently, Guangzhou Wondfo Biotech Co.Ltd(300482) was concerned about the media release entitled Dashenlin Pharmaceutical Group Co.Ltd(603233) the first batch of antigen test kits in Shenzhen store did not arrive Guangzhou Wondfo Biotech Co.Ltd(300482) 19.3 yuan / time, covid-19 antigen self-test products were delayed on the shelves? Or relevant qualifications need to be supplemented “Exclusive Dashenlin Pharmaceutical Group Co.Ltd(603233) and Guangzhou Wondfo Biotech Co.Ltd(300482) signed a strategic cooperation agreement on the sales of covid-19 antigen self-test reagent”, “covid-19 can also be tested at home, and the results will be obtained in 15 minutes! Lbx Pharmacy Chain Joint Stock Company(603883) large pharmacies will soon be the first batch to be sold…”, According to these reports, ” Dashenlin Pharmaceutical Group Co.Ltd(603233) all employees have sent a circle of friends about the upcoming sale of antigen detection reagents”, ” Dashenlin Pharmaceutical Group Co.Ltd(603233) and Guangzhou Wondfo Biotech Co.Ltd(300482) have signed a strategic cooperation agreement on the distribution of covid-19 antigen self-test reagents, and Guangzhou Wondfo Biotech Co.Ltd(300482) covid-19 antigen self-test reagents will be ‘launched’ in Dashenlin Pharmaceutical Group Co.Ltd(603233) offline stores tomorrow” “At present, Guangzhou Wondfo Biotech Co.Ltd(300482) because there is no instruction for replacing antigen detection reagent, it has been required to temporarily take off the shelf in OTC channel and re put on the shelf after replacing the product instruction”. ” Lbx Pharmacy Chain Joint Stock Company(603883) pharmacy has reached cooperation with Guangzhou Guangzhou Wondfo Biotech Co.Ltd(300482) pharmacy. The first batch of covid-19 antigen rapid test products have been in the process of logistics and transportation and are expected to be put on shelves in stores in the near future”. The clarification statement is as follows: at present, for the company, it is the overriding task to make every effort to meet the needs of epidemic prevention and control and provide support for epidemic prevention and control. The company attaches great importance to the above situation. After verification, the company will present the following items as follows: 1. The New Coronavirus antigen detection kit (colloidal gold method) developed by the company was approved by the State Administration of drug supervision and approval in November 3, 2020, and the medical device approval certificate was changed in March 12, 2022. After the change of the above-mentioned medical device approval documents, the company is preparing the production materials before going online according to the approved medical device change registration (filing) documents. As of the date of this announcement, no antigen detection reagent products after the change of registration certificate have been put on the market. 2, as of the date of this announcement, the company has not yet reached a sales agreement with the commercial New Coronavirus retail OTC channel on the Guangzhou Wondfo Biotech Co.Ltd(300482) New Coronavirus antigen detection kit (colloidal gold) product which changed the registration certificate, and has not yet sold such products.
the chairman of Guangzhou Wondfo Biotech Co.Ltd(300482) is Wang Jihua, female, 60 years old, with a master’s degree background; The general manager is Li Wenmei, male, 60 years old, with a master’s degree background.
